[{"from": "human", "value": "Provide a description of this molecule. [C][Branch1][=Branch2][C][N][C][C][N][C][C][N][N]"}, {"from": "gpt", "value": "The molecule is a potent and selective copper (II)-selective chelator. It is a structural analog of linear polyamine compounds, [spermidine] and [spermine]. TETA was first developed in Germany in 1861 and its chelating properties were first recognized in 1925. Initially approved by the FDA in 1985 as a second-line treatment for Wilson's disease, TETA is currently indicated to treat adults with stable Wilson\u2019s disease who are de-coppered and tolerant to [penicillamine].  TETA has been investigated in clinical trials for the treatment of heart failure in patients with diabetes."}]